View Item 

Show simple item record

A randomized, open- label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft- tissue sarcoma
dc.contributor.authorSomaiah, Neeta
dc.contributor.authorVan Tine, Brian Andrew
dc.contributor.authorWahlquist, Amy E.
dc.contributor.authorMilhem, Mohammed M.
dc.contributor.authorHill, Elizabeth G.
dc.contributor.authorGarrett‐mayer, Elizabeth
dc.contributor.authorArmeson, Kent E.
dc.contributor.authorSchuetze, Scott M.
dc.contributor.authorMeyer, Christian F.
dc.contributor.authorReuben, Daniel Y.
dc.contributor.authorElias, Anthony D.
dc.contributor.authorRead, William L.
dc.contributor.authorChawla, Sant P.
dc.contributor.authorKraft, Andrew S.
dc.date.accessioned2021-04-06T02:12:10Z
dc.date.available2022-04-05 22:12:09en
dc.date.available2021-04-06T02:12:10Z
dc.date.issued2021-03-15
dc.identifier.citationSomaiah, Neeta; Van Tine, Brian Andrew; Wahlquist, Amy E.; Milhem, Mohammed M.; Hill, Elizabeth G.; Garrett‐mayer, Elizabeth ; Armeson, Kent E.; Schuetze, Scott M.; Meyer, Christian F.; Reuben, Daniel Y.; Elias, Anthony D.; Read, William L.; Chawla, Sant P.; Kraft, Andrew S. (2021). "A randomized, open- label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft- tissue sarcoma." Cancer (6): 894-904.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/167073
dc.publisherWiley Periodicals, Inc.
dc.subject.otheradverse events
dc.subject.othersoft- tissue sarcoma
dc.subject.othergemcitabine and pazopanib
dc.subject.otherbest overall response
dc.titleA randomized, open- label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft- tissue sarcoma
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167073/1/cncr33216_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167073/2/cncr33216.pdf
dc.identifier.doi10.1002/cncr.33216
dc.identifier.sourceCancer
dc.identifier.citedreferenceVerweij J. Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas. Anticancer Drugs. 1995; 6 ( suppl 4 ): 19 - 24.
dc.identifier.citedreferencePisters P, O- Sullivan B, Maki R. Evidence- based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol. 2007; 25: 1003 - 1008.
dc.identifier.citedreferenceHershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B- cell non- Hodgkin’s lymphoma. J Clin Oncol. 2008; 26: 3159 - 3165.
dc.identifier.citedreferenceVan Glabbeke M, Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline- containing first- line regimens- a European Organization for Research and Treatment of Cancer soft tissue and bone sarcoma group study. J Clin Oncol. 1999; 17: 150 - 157.
dc.identifier.citedreferenceVerweij J. Soft tissue sarcoma trials: one size no longer fits all. J Clin Oncol. 2009; 27: 3085 - 3087.
dc.identifier.citedreferenceDileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007; 109: 1863 - 1869.
dc.identifier.citedreferenceMartin- Liberal J, Lopez- Pousa A, Martinez- Trufero J, et al. Phase II study of gemcitabine plus sirolimus in previously treated patients with advanced soft- tissue sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Target Oncol. 2018; 13: 81 - 87.
dc.identifier.citedreferenceGarcia- Del- Muro X, Lopez- Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011; 29: 2528 - 2533.
dc.identifier.citedreferencePautier P, Penel N, Ray- Coquard I, et al. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as a second- line treatment in patients with advanced leiomyosarcomas: a unicancer French Sarcoma Group study (LMS03 study). Eur J Cancer. 2019; 125: 31 - 37.
dc.identifier.citedreferencePatel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19: 3483 - 3489.
dc.identifier.citedreferenceMerimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmocol. 2000; 45: 177 - 181.
dc.identifier.citedreferenceSvancarova L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft- tissue sarcomas. A phase II study of EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002; 38: 556 - 559.
dc.identifier.citedreferenceSpath- Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K. Phase II trial of gemcitabine in patients with pretreated advanced soft issue sarcomas. Anticancer Drugs. 2000; 11: 325 - 329.
dc.identifier.citedreferencePlummer R, Madi A, Jeffels M, et al. A phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013; 71: 93 - 101.
dc.identifier.citedreferenceCarmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249 - 257.
dc.identifier.citedreferenceSubbah V, Meyer C, Zinner R, et al. Phase Ib/II study of safety and efficacy of combination therapy with multikinase VEGF inhibitor pazopanib and MEK inhibitor trametinib in advanced soft tissue sarcoma. Clin Cancer Res. 2017; 23: 4027 - 4034.
dc.identifier.citedreferenceSamuels BL, Chawla SP, Somaiah N, et al. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate- grade or high- grade liposarcoma. Cancer. 2017; 123: 4640 - 4647.
dc.identifier.citedreferenceVos M, Sleijfer S, Latiere S, et al. Association of pazopanib- induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organization for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. Acta Oncol. 2019; 58: 872 - 879.
dc.identifier.citedreferenceVan der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft- tissue sarcoma (PALETTE): a randomized, double- blind, placebo- controlled phase 3 trial. Lancet. 2012; 379: 1879 - 1886.
dc.identifier.citedreferenceMiyamoto S, Kakutani S, Sato Y, Hanashi A, Kinoshita Y, Ishikawa A. Drug review: pazopanib. Jpn J Clin Oncol. 2018; 48: 503 - 513.
dc.identifier.citedreferenceSeddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first- line treatment in previously untreated advanced unresectable or metastatic soft- tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017; 18: 1397 - 1410. doi: 10.1016/S1470- 2045(17)30622- 8
dc.identifier.citedreferencePautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012; 17: 1213 - 1220.
dc.identifier.citedreferenceMaki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance research through collaboration study. J Clin Oncol. 2007; 25: 2755 - 2763.
dc.identifier.citedreferenceLeu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004; 22: 1706 - 1712.
dc.identifier.citedreferenceJurczak W, Sobocinski M, Joks M, et al. High incidence of cardiovascular mortality caused by acute and early chronic progressive doxorubicin toxicity: retrospective analysis of 606 patients. J Clin Oncol. 2011; 29: e18532.
dc.identifier.citedreferenceLipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23: 2629 - 2636.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr33216_am.pdf
Size:
433.7KB
Format:
PDF
View/Open
Name:
cncr33216.pdf
Size:
225.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.